Susan M. Podlogar - 10 Jul 2026 Form 4 Insider Report for Tevogen Bio Holdings Inc. (TVGN)

Reporting relationship: Director
Issuer ticker: TVGN
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 17:31:18 UTC
Prior SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Kirti Desai, Attorney-in-Fact

Key filing fact

Susan M. Podlogar filed Form 4 for Tevogen Bio Holdings Inc. (TVGN) on 10 Jul 2026.

Key facts

This page summarizes Susan M. Podlogar's Form 4 filing for Tevogen Bio Holdings Inc. (TVGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2026, 17:31.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001709959 Primary reporting owner

PODLOGAR SUSAN M

Relationship: Director
Address: C/O TEVOGEN BIO HOLDINGS INC., 15 INDEPENDENCE BLVD, STE 410, WARREN
Signature: /s/ Kirti Desai, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVGN transaction

Common Stock

Award

Transaction value
Shares: +40,000
Change %: +461%
Price: $0.000000^*
Shares after: 48,678
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.